JP2006503031A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503031A5
JP2006503031A5 JP2004535695A JP2004535695A JP2006503031A5 JP 2006503031 A5 JP2006503031 A5 JP 2006503031A5 JP 2004535695 A JP2004535695 A JP 2004535695A JP 2004535695 A JP2004535695 A JP 2004535695A JP 2006503031 A5 JP2006503031 A5 JP 2006503031A5
Authority
JP
Japan
Prior art keywords
epa
use according
administered
day
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004535695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503031A (ja
Filing date
Publication date
Priority claimed from GBGB0221480.7A external-priority patent/GB0221480D0/en
Application filed filed Critical
Publication of JP2006503031A publication Critical patent/JP2006503031A/ja
Publication of JP2006503031A5 publication Critical patent/JP2006503031A5/ja
Pending legal-status Critical Current

Links

JP2004535695A 2002-09-16 2003-09-16 拒食症(an)及び過食症を治療するためのエイコサペンタエン酸(epa) Pending JP2006503031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (2)

Publication Number Publication Date
JP2006503031A JP2006503031A (ja) 2006-01-26
JP2006503031A5 true JP2006503031A5 (enExample) 2006-11-02

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004535695A Pending JP2006503031A (ja) 2002-09-16 2003-09-16 拒食症(an)及び過食症を治療するためのエイコサペンタエン酸(epa)

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
CN101631542B (zh) 2006-12-28 2011-12-21 三得利控股株式会社 神经再生剂
ES2561482T3 (es) 2007-02-15 2016-02-26 Centre De Recherche Sur Les Biotechnologies Marine Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3318255B1 (en) * 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
BR112013020346A2 (pt) * 2011-02-11 2019-09-24 Du Pont concentrado de ácido eicosapentaenoico, produto farmac~eutico, método de elaboração de um concentrado de ácido eicosapentaenoico e uso de óleo microbiano
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
CN111971041A (zh) 2018-02-07 2020-11-20 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、组合物、方法及其用途
WO2019204218A1 (en) * 2018-04-16 2019-10-24 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CA3054203C (en) 2018-05-03 2021-01-05 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
US12144786B2 (en) 2020-03-27 2024-11-19 Homeostasis Therapeutics LLC Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Similar Documents

Publication Publication Date Title
JP2006503031A5 (enExample)
ES2613606T3 (es) Uso de derivados de ácidos grasos polinsaturados como medicamentos
CN1268328C (zh) 辅酶q与二十碳五烯酸(epa)
RU2005107416A (ru) Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии
US11224585B2 (en) Compositions containing omega-3 oil and uses thereof
TWI285549B (en) Therapeutic combinations of fatty acids
JP2020094072A (ja) ω3脂肪酸の自己乳化組成物
WO2005089744A3 (en) Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CN1343120A (zh) 必需脂肪酸在预防心血管疾病中的应用
JP2014512351A5 (enExample)
CN107074884A (zh) 活性剂的矿物质氨基酸复合物
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
WO2005046668A1 (ja) 言語障害予防・治療剤
GB2504061A (en) Omega-6 Enriched PUFA Phospholipids
JP2020503388A (ja) 悪液質を予防及び/又は処置するためのオメガ−3脂肪酸組成物
Singer ICU nutrition: Treatment and problem solving Topic 18
Brummer Probiotics and gut health—Is food passing pharma?
Calder Immunity on the cutting edge between food and pharma